A novel multiplex cell viability assay for high-throughput RNAi screening

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Gilbert, Daniel F ^a   Erdmann, Gerrit ^a   Zhang, Xian ^a   Fritzsche, Anja ^a   Demir, Kubilay ^a   Jaedicke, Andreas ^a   Muehlenberg, Katja ^b   Wanker, Erich E ^b   Boutros, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; SMALL INTERFERING RNA; ADENOSINE TRIPHOSPHATE; BENZIMIDAZOLE DERIVATIVE; CALCEIN AM; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; HOE 33342;

ARTICLE; CASE STUDY; CELL VIABILITY; COMPUTER PROGRAM; CONTROLLED STUDY; EMBRYO; FALSE POSITIVE RESULT; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LETHALITY; PHENOTYPE; RNA INTERFERENCE; CELL STRAIN HEK293; CELL SURVIVAL; CHEMISTRY; CYTOPLASM; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; REPRODUCIBILITY;

ADENOSINE TRIPHOSPHATE; BENZIMIDAZOLES; CELL SURVIVAL; CYTOPLASM; FALSE POSITIVE REACTIONS; FLUORESCEINS; FLUORESCENT DYES; HEK293 CELLS; HUMANS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 82655180433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028338     Document Type: Article

References (36)

1. Falschlehner C, Steinbrink S, Erdmann G, Boutros M, (2010) High-throughput RNAi screening to dissect cellular pathways: a how-to guide. Biotechnol J 5 (4): 368-76.
2. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, et al. (2009) PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 69 (9): 3955-62.
3. Willingham AT, Deveraux QL, Hampton GM, Aza-Blanc P, (2004) RNAi and HTS: exploring cancer by systematic loss-of-function. Oncogene 23 (51): 8392-400.
4. Einav Y, Shistik E, Shenfeld M, Simons AH, Melton DW, et al. (2003) Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. Mol Cancer Ther 2 (11): 1121-8.
5. Chan DA, Giaccia AJ, (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 10 (5): 351-64.
6. Iglehart JD, Silver DP, (2009) Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361 (2): 189-91.
7. Womac AD, Burkeen JF, Neuendorff N, Earnest DJ, Zoran MJ, (2009) Circadian rhythms of extracellular ATP accumulation in suprachiasmatic nucleus cells and cultured astrocytes. Eur J Neurosci 30 (5): 869-76.
8. Ataullakhanov FI, Vitvitsky VM, (2002) What determines the intracellular ATP concentration. Biosci Rep 22 (5-6): 501-11.
9. das Neves RP, Jones NS, Andreu L, Gupta R, Enver T, et al. (2010) Connecting variability in global transcription rate to mitochondrial variability. PLoS Biol 8 (12): e1000560.
10. Braut-Boucher F, Pichon J, Rat P, Adolphe M, Aubery M, Font J, (1995) A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using Calcein AM-labeled lymphocytes. J Immunol Meth 178: 41-51.
11. Graça da Silveira M, Vitória San Romão M, Loureiro-Dias MC, Rombouts FM, Abee T, (2002) Flow cytometric assessment of membrane integrity of ethanol-stressed Oenococcus oeni cells. Appl Environ Microbiol 68 (12): 6087-93.
12. Larsson R, Nygren P, (1989) A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res 9 (4): 1111-9.
13. Pelz O, Gilsdorf M, Boutros M, (2010) web cellHTS2: a web-application for the analysis of high-throughput screening data. BMC Bioinformatics 11: 185.
14. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, et al. (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107 (17): 7710-5.
15. Mollapour M, Tsutsumi S, Neckers L, (2010) Hsp90 phosphorylation, Wee1, and the cell cycle. Cell Cycle 9 (12).
16. Chen AY, Yu C, Gatto B, Liu LF, (1993) DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 90: 8131-8135.
17. Caviston JP, Zajac AL, Tokito M, Holzbaur EL, (2011) Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes. Mol Biol Cell 22 (4): 478-92.
18. Marcora E, Kennedy MB, (2010) The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus. Hum Mol Genet 19 (22): 4373-84.
19. Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S, (2010) Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J 29 (14): 2433-45.
20. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC, (2002) Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 277 (37): 33791-8.
21. Jin YN, Johnson GV, (2010) The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr 42 (3): 199-205.
22. Chiang MC, Chern Y, Juo CG, (2011) The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. Biochim Biophys Acta 1812 (9): 1111-20.
23. Giacomello M, Hudec R, Lopreiato R, (2011) Huntington's disease, calcium, and mitochondria. Biofactors 37 (3): 206-18.
24. Karachitos A, Gałgańska H, Kmita H, (2010) The role of mitochondria in the pathogenesis of Huntington's disease. Postepy Biochem 56 (2): 174-81.
25. Titus S, Elia N, Southall N, Zheng W, Marugan JJ, et al. (2010) Identification of compounds which inhibit cytotoxicity associated with mutant Huntingtin protein expression. Probe Reports from the NIH Molecular Libraries Program [Internet] Bethesda (MD) National Center for Biotechnology Information (US).
26. King MA, Goemans CG, Hafiz F, Prehn JH, Wyttenbach A, et al. (2008) Cytoplasmic inclusions of Htt exon1 containing an expanded polyglutamine tract suppress execution of apoptosis in sympathetic neurons. J Neurosci 28 (53): 14401-15.
27. Aziz NA, Pijl H, Frölich M, Snel M, Streefland TC, et al. (2010) Systemic energy homeostasis in Huntington's disease patients. J Neurol Neurosurg Psychiatry 81 (11): 1233-7.
28. Steffan JS, (2010) Does Huntingtin play a role in selective macroautophagy? Cell Cycle 9 (17): 3401-13.
29. Martín-Aparicio E, Avila J, Lucas JJ, (2002) Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci 16 (2): 355-9.
30. Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, et al. (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 3 (5): e82.
31. Saji M, Ringel MD, (2010) The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321 (1): 20-8.
32. Tomashevski A, Husseman J, Jin LW, Nochlin D, Vincent I, (2001) Constitutive Wee1 activity in adult brain neurons with M phase-type alterations in Alzheimer neurodegeneration. J Alzheimers Dis 3 (2): 195-207.
33. Ross BM, Moszczynska A, Erlich J, Kish SJ, (1998) Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 70 (2): 786-93.
34. Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, et al. (2009) Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol 215 (1): 191-200.
35. Licchesi JD, Van Neste L, Tiwari VK, Cope L, Lin X, et al. (2010) Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene.
36. Nguyen AV, Albers CG, Holcombe RF, (2010) Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. Int J Mol Med 26 (1): 121-5.